trending Market Intelligence /marketintelligence/en/news-insights/trending/cnnolr07orhow1pz8r5new2 content esgSubNav
In This List

Profound Medical names 2 directors

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Profound Medical names 2 directors

Profound Medical Corp. shareholders elected two new directors at the company's June 14 annual meeting.

Arthur Rosenthal and Brian Ellacott will serve as independent directors of Ontario-based Profound Medical.

Rosenthal is CEO of gEyeCue Ltd., a development stage medical device company. His previous roles include senior vice president and chief scientific officer of Boston Scientific Corp. and vice president of research and development at C. R. Bard Inc., now a unit of Becton Dickinson and Co.

Ellacott is CEO of Belmont Instrument Corp., a medical device company focused on fluid warming and infusion systems. Previously, he was president and CEO of Laborie Medical Technologies.

Medical device company Profound Medical develops and sells technologies to ablate the prostate gland in patients with prostate cancer.